Neil Finnen, MD
Ophthalmology · Carmel, INNPI 1225014848
Payments from drug & device makers
Across 155 payments — averaging $36,104 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5.4M
- Janssen Research & Development, LLC$113K
- Ocular Therapeutix, Inc.$28K
- Eyepoint US, Inc.$7K
- Apellis Pharmaceuticals, Inc.$2K
- AbbVie$571
- plus $2K from 9 others
What the payments were for
- Consulting fees$501%
- Travel & lodging$5,56058%
- Food & beverage$3,93641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 53 | $5,442,162 |
| Janssen Research & Development, LLC | 27 | $113,433 |
| Ocular Therapeutix, Inc. | 11 | $28,311 |
| Eyepoint US, Inc. | 7 | $7,355 |
| Apellis Pharmaceuticals, Inc. | 11 | $2,432 |
| AbbVie(2 entities) | 6 | $571 |
| Alimera Sciences, Inc. | 10 | $405 |
| Astellas Pharma US Inc | 6 | $319 |
| Genentech USA, Inc. | 3 | $284 |
| US Oncology Corporate, Inc. | 1 | $202 |
| ANI Pharmaceuticals, Inc. | 10 | $198 |
| Janssen Global Services, LLC | 1 | $177 |
| Regeneron Healthcare Solutions, Inc. | 7 | $124 |
| Amgen | 1 | $91 |
| Regeneron | 1 | $48 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,596,114 in reported general payments places this provider in the 95th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 247 | $11,647 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 44 | $6,672 |
| ProlensaBromfenac Sodium | 11 | $3,748 |
| RocklatanNetarsudil Mesylat/Latanoprost | 11 | $3,744 |
| Bromfenac Sodium | 13 | $2,562 |
| Acetazolamide | 34 | $2,473 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,310 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 104 | $1,394 |
| Atropine Sulfate | 34 | $1,215 |
| Ondansetron Hcl | 140 | $849 |
| Latanoprost | 134 | $806 |
| ValacyclovirValacyclovir Hcl | 20 | $340 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 88 | $291 |
| ErythromycinErythromycin Base | 20 | $177 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 16 | $170 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Carmel
- Michael BehforouzCarmel$17K
- Michael HopenCarmel$11K
- Thomas CiullaCarmel$7K
- Shamik BafnaLafayette$860K
- Mohamed GendyFort Wayne$813K
- Kevin WaltzIndianapolis$765K
- Francis PriceIndianapolis$500K
- Blair BoehmerIndianapolis$128K
- John LindIndianapolis$125K
- William WhitsonIndianapolis$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.